Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.53 |
| ▸ | MEN1 | O00255 | 11/20 | 0.53 |
| ▸ | POLB | P06746 | 10/20 | 0.53 |
| ▸ | BLM | P54132 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.53 |
| ▸ | USP2 | O75604 | 4/20 | 0.53 |
| ▸ | RECQL | P46063 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922024 | 0.81 | ITGA4 (0.64) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL20718846 | 0.80 | TDP1 (0.54) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL22095990 | 0.76 | ITGA4 (0.70) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL11149259 | 0.75 | POLB (0.50) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL13322146 | 0.75 | STK17B (0.49) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL29489704 | 0.75 | ITGA4 (0.61) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL11149254 | 0.74 | MEN1 (0.73) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL4603774 | 0.72 | MAPT (0.59) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL20718844 | 0.72 | MEN1 (0.59) | MAPTLMNAKMT2AMEN1POLB | |
| SCHEMBL20718840 | 0.72 | ITGA4 (0.58) | MAPTLMNAKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1845781-B1 | USE OF COMPOUNDS DERIVED FROM PYRIMIDINETRIONE AS ACETYL CHOLINESTERASE INHIBITORS, COMPOSITIONS CONTAINING SAID DERIVATIVES, AND THE USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2008-07-09 | — | — | EP | claimed |
| US-9994554-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | NUHOPE, LLC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878998-B2 | Barbiturate and thiobarbiturate compounds for use in cancer therapy | NUHOPE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| WO-2017189700-A1 | NEGATIVE PHOTOCHROMIC MATERIALS WITH TUNABLE PROPERTIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | CONNOR, JAMES R. | 2015-03-05 | — | — | US | disclosed |
| EP-1845781-B1 | USE OF COMPOUNDS DERIVED FROM PYRIMIDINETRIONE AS ACETYL CHOLINESTERASE INHIBITORS, COMPOSITIONS CONTAINING SAID DERIVATIVES, AND THE USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134691-A1 | BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAX | MAPT 2828/4885LMNA 3144/4885KMT2A 2749/4885 |
| US-20150065531-A1 | COMPOUNDS FOR USE IN CANCER THERAPY | MGMT, BCL2, BAK1 | MAPT 3272/4885LMNA 1907/4885KMT2A 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.